Control of HIV infection by IFN-α: implications for latency and a cure

被引:0
作者
Nollaig M. Bourke
Silvia Napoletano
Ciaran Bannan
Suaad Ahmed
Colm Bergin
Áine McKnight
Nigel J. Stevenson
机构
[1] Trinity Translational Medicine Institute,School of Medicine
[2] Trinity College Dublin,Department of Medical Gerontology
[3] Mercer’s Institute for Successful Ageing,School of Biochemistry and Immunology
[4] St. James Hospital,Department of Genito Urinary Medicine and Infectious Diseases
[5] Trinity College Dublin,Blizard Institute School of Medicine and Dentistry
[6] St. James’s Hospital,undefined
[7] Queen Mary University of London,undefined
来源
Cellular and Molecular Life Sciences | 2018年 / 75卷
关键词
HIV; Interferon; Latency; Anti-viral; JAK/STAT; Cure;
D O I
暂无
中图分类号
学科分类号
摘要
Viral infections, including HIV, trigger the production of type I interferons (IFNs), which in turn, activate a signalling cascade that ultimately culminates with the expression of anti-viral proteins. Mounting evidence suggests that type I IFNs, in particular IFN-α, play a pivotal role in limiting acute HIV infection. Highly active anti-retroviral treatment reduces viral load and increases life expectancy in HIV positive patients; however, it fails to fully eliminate latent HIV reservoirs. To revisit HIV as a curable disease, this article reviews a body of literature that highlights type I IFNs as mediators in the control of HIV infection, with particular focus on the anti-HIV restriction factors induced and/or activated by IFN-α. In addition, we discuss the relevance of type I IFN treatment in the context of HIV latency reversal, novel therapeutic intervention strategies and the potential for full HIV clearance.
引用
收藏
页码:775 / 783
页数:8
相关论文
共 648 条
  • [21] Kawai T(2016)Identification of interferon-stimulated genes with antiretroviral activity Cell Host Microbe 20 392-311
  • [22] Akira S(2004)The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys Nature 427 848-1821
  • [23] Beignon AS(2012)Recruitment and dynamics of proteasome association with rhTRIM5alpha cytoplasmic complexes during HIV-1 infection Traffic 13 1206-1663
  • [24] McKenna K(2008)Proteasomal degradation of TRIM5alpha during retrovirus restriction PLoS Pathog 4 e1000074-452
  • [25] Skoberne M(2011)An HIV-1 resistance polymorphism in TRIM5alpha gene among Chinese intravenous drug users J Acquir Immune Defic Syndr 56 306-1407
  • [26] Manches O(2010)A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort AIDS 24 1813-6076
  • [27] DaSilva I(2009)Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection J Infect Dis 199 1657-288
  • [28] Kavanagh DG(2008)The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection PLoS Pathog 4 e18-382
  • [29] Larsson M(2016)Receptor usage dictates HIV-1 restriction by human TRIM5α in dendritic cell subsets Nature 540 448-228
  • [30] Gorelick RJ(2003)The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif Nat Med 9 1404-1043